ABL Bio Advances B7-H3xROR1 ADC ABL206 Into Early Clinical Stage

According to a recent LinkedIn post from BioSpectator Inc, South Korea–based ABL Bio is pursuing a B7-H3xROR1 bispecific antibody-drug conjugate (ADC) strategy to address limitations of existing B7-H3 ADCs, including I-DXd. The post notes that ABL Bio obtained U.S. FDA clearance in January for a Phase 1 trial of ABL206 (NEOK001), with first patient dosing anticipated around late May.

The LinkedIn post highlights comments from an ABL Bio ADC division director indicating that development is focused on solid tumors co-expressing B7-H3 and ROR1 to improve tumor specificity. The rationale, as described, is that while B7-H3 shows broad expression, ROR1 is more selective, which could potentially reduce toxicity in normal tissues.

As referenced in the post, preclinical data suggest that in models where tumors regrew after I-DXd treatment, subsequent administration of ABL206 was associated with reduced tumor growth. The post also cites favorable tolerability in non-human primates, with an identified highest non-severely toxic dose of 60 mg/kg for ABL206, implying a potentially wide safety margin for early clinical testing.

For investors tracking the ADC space, the described progress of ABL206 may indicate emerging competition in next-generation solid tumor ADCs targeting B7-H3 and ROR1. If early human data validate the preclinical efficacy and safety profile mentioned in the post, this could enhance ABL Bio’s partnering prospects and valuation, and may be relevant to companies and funds exposed to the oncology biologics and ADC value chain.